Head-to-head · 2026-05-18
Compare Peptide Sample Deals 2026
Every peptide-sample decision in 2026 comes down to a handful of head-to-heads: GHRH choice (sermorelin vs CJC-1295 starter samples), GHRH-vs-GHRP framing (sermorelin vs ipamorelin combo, CJC-1295 vs ipamorelin combo), educational context on Cat-2 molecules (BPC-157 vs TB-500 — both research-only, no vendor links), and specialty-clinic intake choice (Marek Health vs Defy Medical). Each comparison below is a side-by-side editorial covering mechanism, sample pricing, regulatory posture, and the specific patient profile each pick fits best.
Head-to-head · Clinical peptides
Sermorelin vs. Ipamorelin
Sermorelin vs ipamorelin in 2026 — different mechanisms, different roles, almost always used together. The GHRH vs GHRP comparison every peptide patient should understand.
Read comparison →
Head-to-head · Clinical peptides
CJC-1295 vs. Ipamorelin
CJC-1295 vs ipamorelin in 2026 — different mechanisms, different roles, used together for GHRH + GHRP synergy. Plus the DAC vs no-DAC choice on the CJC side.
Read comparison →
Head-to-head · Educational only
BPC-157 vs. TB-500
BPC-157 vs TB-500 in 2026 — the most-marketed 'recovery stack' peptide pair. Both Cat-2 listed, neither available through legitimate clinical channels. The educational context plus the legitimate alternatives.
Read comparison →
Head-to-head · Specialty peptide clinics
Marek Health vs. Defy Medical
Marek Health vs Defy Medical for peptide therapy in 2026 — the two go-to specialty clinics for clinical peptide protocols. Pricing, formulary depth, clinical model compared.
Read comparison →